VRTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.20%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $41,395,983.90

Vertex Pharmaceuticals Insider Trading History Chart

Vertex Pharmaceuticals Share Price & Price History

^$395.98

▼ -1.5 (-0.38%)

As of 04/29/2024 03:28 PM ET

Days: 30 | 90 | 365

Have You Seen Elon’s New A.I. Device? (Picture Inside)

From InvestorPlace | Ad

A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...

This strange new device to protect us against that A.I. threat...

Vertex Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/26/2024	Ourania Tatsis	EVP	Sell	354	$425.70	$150,697.80	55,804
2/20/2024	Ourania Tatsis	EVP	Sell	480	$420.79	$201,979.20	59,827
2/12/2024	Amit Sachdev	EVP	Sell	3,222	$420.24	$1,354,013.28	74,364
2/12/2024	Jeffrey M. Leiden	Chairman	Sell	2,656	$419.51	$1,114,218.56	27,644
2/12/2024	Kristen Ambrose	CAO	Sell	1,374	$420.24	$577,409.76	9,676
2/12/2024	Stuart A. Arbuckle	COO	Sell	4,295	$420.24	$1,804,930.80	75,718
1/8/2024	Jeffrey M. Leiden	Chairman	Sell	6,648	$419.07	$2,785,977.36	2,423
11/6/2023	Bruce I. Sachs	Director	Sell	11,250	$385.00	$4,331,250.00	40,000
10/31/2023	Carmen Bozic	CMO	Sell	5,651	$355.92	$2,011,303.92	34,952
10/17/2023	Carmen Bozic	CMO	Sell	5,651	$373.25	$2,109,235.75	40,603
10/17/2023	Sangeeta N Bhatia	Director	Sell	243	$375.00	$91,125.00	3,901
10/16/2023	Jeffrey M. Leiden	Chairman	Sell	12,962	$374.00	$4,847,788.00	22,425
10/6/2023	Sangeeta N Bhatia	Director	Sell	242	$360.00	$87,120.00	4,144
10/3/2023	Carmen Bozic	CMO	Sell	5,651	$345.28	$1,951,177.28	46,254
10/2/2023	Jonathan Biller	EVP	Sell	610	$346.76	$211,523.60	10,569
9/19/2023	Carmen Bozic	CMO	Sell	5,651	$351.00	$1,983,501.00	51,905
8/23/2023	Ourania Tatsis	EVP	Sell	2,500	$355.00	$887,500.00	48,637
8/9/2023	David Altshuler	EVP	Sell	63	$345.51	$21,767.13	32,038
8/9/2023	Sangeeta N Bhatia	Director	Sell	242	$345.51	$83,613.42	4,386
7/17/2023	Bruce I. Sachs	Director	Sell	11,250	$356.75	$4,013,437.50	40,000
7/17/2023	Reshma Kewalramani	CEO	Sell	7,828	$355.00	$2,778,940.00	118,906
6/15/2023	Stuart A. Arbuckle	COO	Sell	8,603	$349.00	$3,002,447.00	56,556
5/30/2023	Kristen Ambrose	CAO	Sell	289	$329.82	$95,317.98	6,838
5/30/2023	Stuart A. Arbuckle	COO	Sell	82	$329.82	$27,045.24	56,556
5/8/2023	Bastiano Sanna	EVP	Sell	2,850	$350.00	$997,500.00	32,038
5/8/2023	Jeffrey M. Leiden	Chairman	Sell	1,125	$349.00	$392,625.00	35,387
5/5/2023	Bastiano Sanna	EVP	Sell	422	$350.03	$147,712.66	34,888
5/5/2023	Jeffrey M. Leiden	Chairman	Sell	879	$349.56	$307,263.24	36,512
5/2/2023	Bastiano Sanna	EVP	Sell	1,622	$350.66	$568,770.52	38,091
5/2/2023	Jeffrey M. Leiden	Chairman	Sell	6,450	$349.89	$2,256,790.50	41,899
5/2/2023	Sangeeta N Bhatia	Director	Sell	580	$348.28	$202,002.40	4,628
4/27/2023	Reshma Kewalramani	CEO	Sell	3,317	$339.08	$1,124,728.36	126,652
4/12/2023	Bastiano Sanna	EVP	Sell	7,567	$326.70	$2,472,138.90	39,713
4/12/2023	Bruce I. Sachs	Director	Sell	21,300	$326.73	$6,959,349.00	41,210
4/4/2023	Bastiano Sanna	EVP	Sell	522	$315.81	$164,852.82	47,280
3/24/2023	Charles F. Wagner, Jr.	CFO	Sell	1,768	$305.38	$539,911.84	49,611
3/17/2023	Charles F. Wagner, Jr.	CFO	Sell	2,000	$296.39	$592,780.00	51,379
3/16/2023	Bastiano Sanna	EVP	Sell	2,746	$300.59	$825,420.14	49,268
3/13/2023	Charles F. Wagner, Jr.	CFO	Sell	2,666	$293.83	$783,350.78	53,379
3/10/2023	Charles F. Wagner, Jr.	CFO	Sell	2,088	$289.61	$604,705.68	56,045
2/27/2023	Kristen Ambrose	CAO	Sell	1,207	$287.55	$347,072.85	7,303
2/27/2023	Ourania Tatsis	EVP	Sell	354	$287.48	$101,767.92	56,805
2/27/2023	Stuart A. Arbuckle	COO	Sell	5,034	$287.47	$1,447,123.98	56,556
2/22/2023	Stuart A. Arbuckle	COO	Sell	2,401	$294.33	$706,686.33	66,304
2/13/2023	Ourania Tatsis	EVP	Sell	275	$298.99	$82,222.25	65,765
2/13/2023	Stuart A. Arbuckle	COO	Sell	4,887	$298.92	$1,460,822.04	82,003
2/6/2023	David Altshuler	EVP	Sell	1,304	$306.00	$399,024.00	68,645
1/30/2023	Lloyd Carney	Director	Sell	2,700	$320.52	$865,404.00	4,150
1/27/2023	Yuchun Lee	Director	Sell	1,429	$322.03	$460,180.87	1,875
1/25/2023	Reshma Kewalramani	CEO	Sell	10,000	$315.05	$3,150,500.00	89,598
1/25/2023	Yuchun Lee	Director	Sell	4,000	$313.96	$1,255,840.00	1,875
1/23/2023	Yuchun Lee	Director	Sell	2,129	$312.02	$664,290.58	1,875
1/18/2023	Yuchun Lee	Director	Sell	442	$312.17	$137,979.14	1,875
11/7/2022	David Altshuler	EVP	Sell	1,303	$303.04	$394,861.12	36,077
10/24/2022	Sangeeta N Bhatia	Director	Sell	621	$310.00	$192,510.00	4,040
10/18/2022	Bastiano Sanna	EVP	Sell	1,791	$300.31	$537,855.21	39,192
8/15/2022	Joy Liu	SVP	Sell	3,747	$303.90	$1,138,713.30	9,605
8/15/2022	Reshma Kewalramani	CEO	Sell	11,689	$305.06	$3,565,846.34	99,598
8/15/2022	Stuart A. Arbuckle	COO	Sell	22,173	$303.93	$6,739,039.89	45,278
8/9/2022	Joy Liu	SVP	Sell	946	$300.00	$283,800.00	13,388
8/9/2022	Ourania Tatsis	EVP	Sell	1,400	$298.97	$418,558.00	46,090
8/9/2022	Stuart A. Arbuckle	COO	Sell	5,690	$300.67	$1,710,812.30	60,996
8/8/2022	Sangeeta N Bhatia	Director	Sell	621	$293.03	$181,971.63	4,661
7/29/2022	Sangeeta N Bhatia	Director	Sell	621	$278.77	$173,116.17	5,282
7/25/2022	Jeffrey M. Leiden	Chairman	Sell	132,079	$281.38	$37,164,389.02	2,423
7/19/2022	David Altshuler	EVP	Sell	17,865	$288.65	$5,156,732.25	36,077
6/24/2022	Reshma Kewalramani	CEO	Sell	11,689	$291.30	$3,405,005.70	111,153
5/4/2022	Bastiano Sanna	EVP	Sell	36	$275.09	$9,903.24	41,660
5/2/2022	Bastiano Sanna	EVP	Sell	320	$259.16	$82,931.20	41,696
5/2/2022	Charles F. Wagner, Jr.	CFO	Sell	343	$258.83	$88,778.69	42,730
5/2/2022	Sangeeta N Bhatia	Director	Sell	737	$258.94	$190,838.78	5,903
5/2/2022	Stuart A. Arbuckle	COO	Sell	306	$263.98	$80,777.88	64,760
4/29/2022	Joy Liu	SVP	Sell	120	$275.41	$33,049.20	14,334
4/25/2022	Kristen Ambrose	CAO	Sell	327	$269.55	$88,142.85	3,496
4/18/2022	Yuchun Lee	Director	Sell	2,000	$284.23	$568,460.00	1,875
4/13/2022	Jeffrey M. Leiden	Chairman	Sell	15,789	$289.04	$4,563,652.56	74,160
4/13/2022	Yuchun Lee	Director	Sell	2,000	$287.50	$575,000.00	1,875
4/11/2022	Yuchun Lee	Director	Sell	2,000	$280.30	$560,600.00	1,875
4/7/2022	Bastiano Sanna	EVP	Sell	561	$276.18	$154,936.98	42,782
4/7/2022	Yuchun Lee	Director	Sell	2,000	$274.86	$549,720.00	1,099
4/4/2022	Bastiano Sanna	EVP	Sell	562	$267.71	$150,453.02	43,343
4/4/2022	Yuchun Lee	Director	Sell	2,000	$267.72	$535,440.00	1,875
4/1/2022	Charles F. Wagner, Jr.	CFO	Sell	2,582	$264.76	$683,610.32	43,620
3/31/2022	Margaret G. McGlynn	Director	Sell	5,000	$262.27	$1,311,350.00	1,099
3/17/2022	Charles F. Wagner, Jr.	CFO	Sell	3,171	$250.15	$793,225.65
3/17/2022	Ourania Tatsis	EVP	Sell	2,833	$250.11	$708,561.63
2/25/2022	Ourania Tatsis	EVP	Sell	325	$230.95	$75,058.75
2/18/2022	Ourania Tatsis	EVP	Sell	519	$231.00	$119,889.00
2/11/2022	David Altshuler	EVP	Sell	2,297	$235.02	$539,840.94
2/2/2022	Bastiano Sanna	EVP	Sell	1,040	$250.98	$261,019.20
2/2/2022	Charles F. Wagner, Jr.	CFO	Sell	2,944	$250.07	$736,206.08
1/28/2022	Margaret G. McGlynn	Director	Sell	5,000	$241.79	$1,208,950.00
11/15/2021	Amit Sachdev	EVP	Sell	51	$187.19	$9,546.69
11/15/2021	Stuart A. Arbuckle	COO	Sell	3	$187.26	$561.78
8/19/2021	Reshma Kewalramani	CEO	Buy	10,000	$195.65	$1,956,500.00	69,511
6/2/2021	Sangeeta N. Bhatia	Director	Sell	559	$209.69	$117,216.71	5,465
5/3/2021	Bastiano Sanna	EVP	Sell	960	$218.43	$209,692.80	35,068

Healthcare Takes A Big Step Forward With The Help Of AI

From The Bull Report | Ad

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

Click here to see why this small company is trusted by the Mayo Clinic

SEC Filings (Institutional Ownership Changes) for Vertex Pharmaceuticals (NASDAQ:VRTX)

90.96% of Vertex Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Vertex Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/29/2024	Summit Global Investments	41,909	$17.52M	1.3%	-43.8%	0.016%
4/29/2024	China Universal Asset Management Co. Ltd.	51,072	$21.35M	2.7%	+34.1%	0.020%
4/29/2024	Baxter Bros Inc.	1,026	$0.43M	0.1%	+14.5%	0.000%
4/27/2024	Conning Inc.	1,488	$0.62M	0.0%	-2.6%	0.001%
4/27/2024	Foster Victor Wealth Advisors LLC	33,770	$13.52M	1.2%	+9.3%	0.013%
4/27/2024	BayBridge Capital Group LLC	908	$0.36M	0.3%	-65.7%	0.000%
4/26/2024	Pinnacle Associates Ltd.	9,129	$3.82M	0.1%	+51.2%	0.004%
4/26/2024	Securian Asset Management Inc.	15,179	$6.35M	0.2%	-7.0%	0.006%
4/26/2024	Triasima Portfolio Management inc.	11,502	$4.81M	0.4%	-10.2%	0.004%
4/26/2024	UMB Bank n.a.	6,392	$2.67M	0.0%	-82.5%	0.002%
4/26/2024	Arcataur Capital Management LLC	1,660	$0.69M	0.2%	-27.0%	0.001%
4/26/2024	Highview Capital Management LLC DE	5,425	$2.27M	1.0%	+6.8%	0.002%
4/26/2024	Northwest Bancshares Inc.	16,375	$6.85M	1.1%	-3.1%	0.006%
4/26/2024	Renaissance Group LLC	77,696	$32.48M	1.2%	-12.6%	0.030%
4/26/2024	Yousif Capital Management LLC	29,064	$12.15M	0.1%	-6.9%	0.011%
4/26/2024	Schmidt P J Investment Management Inc.	968	$0.41M	0.1%	+6.4%	0.000%
4/26/2024	YHB Investment Advisors Inc.	91	$38K	0.0%	N/A	0.000%
4/26/2024	ZWJ Investment Counsel Inc.	1,695	$0.71M	0.0%	+189.2%	0.001%
4/26/2024	SYSTM Wealth Solutions LLC	1,314	$0.55M	0.1%	-43.4%	0.001%
4/26/2024	Sumitomo Life Insurance Co.	7,698	$3.22M	0.1%	-2.8%	0.003%
4/26/2024	LifePro Asset Management	563	$0.24M	0.2%	N/A	0.000%
4/26/2024	Sigma Investment Counselors Inc.	8,162	$3.41M	0.2%	+12.5%	0.003%
4/26/2024	Terra Nova Asset Management LLC	657	$0.28M	0.2%	+12.9%	0.000%
4/26/2024	Bogart Wealth LLC	18,482	$7.73M	0.4%	+3.8%	0.007%
4/25/2024	Lindbrook Capital LLC	30,188	$12.62M	1.2%	+169.7%	0.012%
4/25/2024	New York State Teachers Retirement System	266,302	$111.32M	0.2%	-2.3%	0.103%
4/25/2024	Mendota Financial Group LLC	80	$33K	0.0%	-33.9%	0.000%
4/25/2024	Bank of New York Mellon Corp	1,874,129	$783.41M	0.2%	-5.2%	0.725%
4/25/2024	Strategy Asset Managers LLC	2,398	$1M	0.2%	-38.3%	0.001%
4/25/2024	Kinneret Advisory LLC	10,094	$4.22M	0.4%	-0.3%	0.004%
4/25/2024	Capital Investment Advisory Services LLC	5,862	$2.45M	0.3%	-0.8%	0.002%
4/25/2024	Zurcher Kantonalbank Zurich Cantonalbank	434,334	$181.56M	0.6%	-2.4%	0.168%
4/25/2024	Fjarde AP Fonden Fourth Swedish National Pension Fund	70,988	$29.67M	0.3%	+2.9%	0.027%
4/25/2024	Aaron Wealth Advisors LLC	2,696	$1.13M	0.2%	+5.4%	0.001%
4/25/2024	Valeo Financial Advisors LLC	6,338	$2.54M	0.1%	+13.1%	0.002%
4/25/2024	Telos Capital Management Inc.	15,470	$6.47M	0.7%	+2.6%	0.006%
4/25/2024	Freedom Day Solutions LLC	5,654	$2.36M	0.8%	-0.9%	0.002%
4/25/2024	Summit Financial LLC	542	$0.23M	0.0%	-36.5%	0.000%
4/25/2024	Heirloom Wealth Management	17,551	$7.34M	2.5%	-1.6%	0.007%
4/24/2024	Private Trust Co. NA	1,440	$0.60M	0.1%	+7.8%	0.001%
4/24/2024	Leavell Investment Management Inc.	4,662	$1.95M	0.1%	N/A	0.002%
4/24/2024	Zhang Financial LLC	3,775	$1.58M	0.1%	+14.2%	0.001%
4/24/2024	CENTRAL TRUST Co	10,175	$4.25M	0.1%	-2.6%	0.004%
4/24/2024	V Square Quantitative Management LLC	3,440	$1.44M	0.2%	+44.1%	0.001%
4/24/2024	Oxler Private Wealth LLC	1,784	$0.75M	0.3%	N/A	0.001%
4/24/2024	Dakota Wealth Management	32,382	$13.54M	0.3%	+39.9%	0.013%
4/24/2024	Simplicity Wealth LLC	28,487	$11.91M	0.3%	N/A	0.011%
4/24/2024	Childress Capital Advisors LLC	800	$0.33M	0.1%	-7.9%	0.000%
4/24/2024	Spire Wealth Management	20,055	$8.38M	0.3%	-2.9%	0.008%
4/24/2024	First Pacific Financial	898	$0.38M	0.1%	+7.4%	0.000%
4/24/2024	Essex Financial Services Inc.	677	$0.28M	0.0%	+5.8%	0.000%
4/24/2024	Assenagon Asset Management S.A.	323,088	$135.05M	0.3%	+9.1%	0.125%
4/23/2024	Global Retirement Partners LLC	1,309	$0.55M	0.0%	+11.0%	0.001%
4/23/2024	TriaGen Wealth Management LLC	4,478	$1.87M	0.8%	-27.5%	0.002%
4/23/2024	Cookson Peirce & Co. Inc.	142,982	$59.77M	3.2%	-0.7%	0.055%
4/23/2024	Covenant Asset Management LLC	12,093	$5.06M	0.8%	+7.1%	0.005%
4/23/2024	Louisiana State Employees Retirement System	35,300	$14.76M	0.3%	-2.2%	0.014%
4/23/2024	Sage Mountain Advisors LLC	741	$0.31M	0.0%	+9.3%	0.000%
4/23/2024	Moody Lynn & Lieberson LLC	61,972	$25.91M	1.7%	+4.1%	0.024%
4/23/2024	United Asset Strategies Inc.	1,470	$0.61M	0.1%	N/A	0.001%
4/23/2024	Wealth Advisory Solutions LLC	503	$0.21M	0.1%	N/A	0.000%
4/23/2024	WASHINGTON TRUST Co	734	$0.31M	0.0%	+6.2%	0.000%
4/23/2024	Cherry Creek Investment Advisors Inc.	2,829	$1.18M	0.6%	+179.3%	0.001%
4/23/2024	Amalgamated Bank	55,608	$23.25M	0.2%	-13.8%	0.022%
4/23/2024	Hall Laurie J Trustee	4,585	$1.92M	0.7%	+1,428.3%	0.002%
4/23/2024	F M Investments LLC	4,101	$1.71M	1.2%	-0.7%	0.002%
4/23/2024	Nations Financial Group Inc. IA ADV	3,788	$1.58M	0.1%	+14.1%	0.001%
4/23/2024	New Mexico Educational Retirement Board	13,000	$5.43M	0.2%	-3.0%	0.005%
4/23/2024	Fifth Third Bancorp	26,741	$11.18M	0.0%	-1.2%	0.010%
4/23/2024	McAdam LLC	2,032	$0.85M	0.1%	+1.8%	0.001%
4/23/2024	Summit Trail Advisors LLC	2,509	$1.05M	0.0%	+19.5%	0.001%
4/23/2024	Strategic Blueprint LLC	960	$0.40M	0.0%	+46.3%	0.000%
4/23/2024	Cigna Investments Inc. New	2,737	$1.14M	0.2%	-1.0%	0.001%
4/23/2024	Raymond James Financial Services Advisors Inc.	29,897	$12.50M	0.0%	+15.4%	0.012%
4/23/2024	Stonegate Investment Group LLC	3,144	$1.31M	0.0%	-4.0%	0.001%
4/23/2024	Sapient Capital LLC	35,275	$14.75M	0.3%	+2.3%	0.014%
4/22/2024	Nicholas Hoffman & Company LLC.	732	$0.31M	0.0%	+15.1%	0.000%
4/22/2024	Kessler Investment Group LLC	13,512	$5.65M	3.5%	+4.0%	0.005%
4/22/2024	Nilsine Partners LLC	3,481	$1.46M	0.2%	-2.0%	0.001%
4/22/2024	PFG Investments LLC	2,009	$0.84M	0.1%	+11.6%	0.001%
4/22/2024	Parsons Capital Management Inc. RI	2,671	$1.12M	0.1%	+239.4%	0.001%
4/22/2024	Outlook Wealth Advisors LLC	629	$0.26M	0.1%	N/A	0.000%
4/22/2024	Raymond James & Associates	318,757	$133.24M	0.1%	-6.9%	0.123%
4/22/2024	Signature Wealth Management Group	1,641	$0.65M	0.3%	N/A	0.001%
4/22/2024	MBL Wealth LLC	888	$0.37M	0.0%	N/A	0.000%
4/22/2024	IFM Investors Pty Ltd	52,453	$21.93M	0.2%	-0.4%	0.020%
4/22/2024	Everpar Advisors LLC	550	$0.23M	0.1%	N/A	0.000%
4/22/2024	Cassia Capital Partners LLC	1,676	$0.70M	0.5%	+28.6%	0.001%
4/22/2024	Ashton Thomas Private Wealth LLC	2,246	$0.94M	0.1%	+15.4%	0.001%
4/22/2024	Strategic Advisors LLC	556	$0.23M	0.0%	+5.9%	0.000%
4/20/2024	Maryland State Retirement & Pension System	20,227	$7.95M	0.2%	+0.9%	0.008%
4/19/2024	Teamwork Financial Advisors LLC	21,252	$8.88M	1.4%	+922.2%	0.008%
4/19/2024	Veracity Capital LLC	1,416	$0.59M	0.2%	+14.3%	0.001%
4/19/2024	Marshall Financial Group LLC	4,835	$2.02M	0.6%	+3.6%	0.002%
4/19/2024	FCG Investment Co	2,310	$0.97M	0.8%	-31.6%	0.001%
4/19/2024	Retirement Guys Formula LLC	2,922	$1.22M	0.6%	+9.4%	0.001%
4/19/2024	New Century Financial Group LLC	1,536	$0.64M	0.4%	-13.0%	0.001%
4/19/2024	ZRC Wealth Management LLC	94	$39K	0.0%	N/A	0.000%
4/19/2024	First Trust Direct Indexing L.P.	4,118	$1.72M	0.1%	+19.3%	0.002%
4/19/2024	Norden Group LLC	13,958	$5.84M	0.1%	+2,169.6%	0.005%

Data available starting January 2016

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $395.98

$395.67

$399.31

50 Day Range

MA: $411.60

$393.10

$433.48

52 Week Range

Now: $395.98

$320.01

$448.40

Volume

322,736 shs

Average Volume

1,216,673 shs

Market Capitalization

$102.34 billion

P/E Ratio

28.51

Dividend Yield

N/A

Beta

0.35

Who are the company insiders with the largest holdings of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top insider shareholders include:
Reshma Kewalramani (CEO)
Stuart A Arbuckle (COO)
Amit Sachdev (EVP)
David Altshuler (EVP)
Ourania Tatsis (EVP)
Charles F Wagner Jr (CFO)
Carmen Bozic (CMO)
Bastiano Sanna (EVP)
Jeffrey M Leiden (Chairman)
Bruce I Sachs (Director)
Joy Liu (SVP)
Jonathan Biller (EVP)
Kristen Ambrose (CAO)
Sangeeta N Bhatia (Director)
Lloyd Carney (Director)
Yuchun Lee (Director)
Learn More about top insider investors at Vertex Pharmaceuticals.
Who are the major institutional investors of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top institutional investors include:
Bank of New York Mellon Corp — 0.73%
Sumitomo Mitsui Trust Holdings Inc. — 0.28%
Zurcher Kantonalbank Zurich Cantonalbank — 0.17%
Global Assets Advisory LLC — 0.13%
Assenagon Asset Management S.A. — 0.13%
Raymond James & Associates — 0.12%
Learn More about top institutional investors of Vertex Pharmaceuticals stock.
Which major investors are selling Vertex Pharmaceuticals stock?: Within the previous quarter, VRTX stock was sold by these institutional investors:
Los Angeles Capital Management LLC
Bank of New York Mellon Corp
Summit Global Investments
UMB Bank n.a.
Raymond James & Associates
Renaissance Group LLC
Zurcher Kantonalbank Zurich Cantonalbank
Perpetual Ltd
In the last year, company insiders that have sold Vertex Pharmaceuticals company stock include:
Reshma Kewalramani (CEO)
Stuart A Arbuckle (COO)
Amit Sachdev (EVP)
David Altshuler (EVP)
Ourania Tatsis (EVP)
Charles F Wagner Jr (CFO)
Carmen Bozic (CMO)
Bastiano Sanna (EVP)
Jeffrey M Leiden (Chairman)
Bruce I Sachs (Director)
Joy Liu (SVP)
Jonathan Biller (EVP)
Learn More investors selling Vertex Pharmaceuticals stock.
Which major investors are buying Vertex Pharmaceuticals stock?: During the previous quarter, VRTX stock was acquired by institutional investors including:
Global Assets Advisory LLC
Simplex Trading LLC
Simplicity Wealth LLC
Assenagon Asset Management S.A.
Teamwork Financial Advisors LLC
Lindbrook Capital LLC
Allspring Global Investments Holdings LLC
Norden Group LLC